Biofluid Proteomic Biomarker Discovery in a Large Animal Model of CLN2 Neuronal Ceroid Lipofuscinosis.
8 affiliations
- 1Department of Ophthalmology, School of Medicine, University of Missouri, Columbia, MO 65212, USA.
- 2Department of Pediatrics, Washington University in St. Louis, St. Louis, MO 63110, USA.
- 3Department of Biomedical Sciences, Joan C. Edwards School of Medicine, Marshall University, Huntington, WV 25701, USA.
- 4Christopher S. Bond Life Science Center, University of Missouri, Columbia, MO 65211, USA.
- 5MU Institute for Data Science and Informatics, University of Missouri, Columbia, MO 65211, USA.
- 6Department of Biomedical Informatics, Biostatistics and Medical Epidemiology, School of Medicine, University of Missouri, Columbia, MO 65211, USA.
- 7Gehrke Proteomics Center, University of Missouri, Columbia, MO 65211, USA.
- 8Department of Veterinary Medicine & Surgery, College of Veterinary Medicine, University of Missouri, Columbia, MO 65211, USA.
Abstract
CLN2 disease is a fatal lysosomal storage disorder caused by deficiency of the lysosomal enzyme tripeptidyl peptidase 1 (TPP1), resulting in progressive neurodegeneration and non-neuronal pathology. While enzyme replacement therapy has improved disease management, there remains a critical need for objective molecular biomarkers capable of monitoring disease progression and therapeutic response. The purpose of this study was to utilize a canine model of CLN2 disease to investigate proteomic changes in cerebrospinal fluid (CSF) and in minimally invasive biofluids tears and plasma to identify candidate disease biomarkers. Untargeted proteomic analysis was conducted using these biofluids from unaffected controls and CLN2-affected dogs at presymptomatic, symptomatic, and advanced disease stages. CSF demonstrated the greatest degree of proteomic alterations over the disease progression. Proteins associated with cytoskeletal organization, synaptic signaling, lysosomal biology, mitochondrial metabolism, lipid homeostasis, and inflammatory responses were significantly altered. Tear fluid demonstrated overlapping biological themes with CSF, particularly involving mitochondrial metabolism, lysosomal function, and lipid-associated pathways. In contrast, plasma proteomic alterations were comparatively modest but supported systemic changes associated with extracellular signaling, inflammation, and lipid metabolism. Collectively, these findings demonstrate progressive and coordinated proteomic alterations across multiple biofluids in CLN2 disease that can serve as candidate biomarkers of disease progression.
Related
- Biofluid Biomarkers of Neuronal and Glial Injury in Epilepsy and Seizures: A Comprehensive Review
- Electroacupuncture attenuates high-salt-induced hypertension by modulating neuronal excitability and proteomic signatures in the paraventricular nucleus of mice
- Circulating SCGB3A2 Is Associated With Impaired Coronary Collateralization in Patients With Chronic Total Occlusion and Type 2 Diabetes: A Proteomic Discovery and Validation Study
- Reproducible cerebrospinal fluid proteomic signatures across early neuronal α-synuclein disease stages in PPMI
- Convergence of Cerebrospinal Fluid Neuronal Biomarker Burden and MRI Lesion Pattern and Its Association With Short-Term Outcome in Neuroinfectious Diseases.
BibTeX
@article{morganjack2026biofluid,
title = {{Biofluid Proteomic Biomarker Discovery in a Large Animal Model of CLN2 Neuronal Ceroid Lipofuscinosis.}},
author = {Brandie R Morgan-Jack and Grace R Kick and Zhen Lyu and Trupti Joshi and Brian Mooney and Joan R Coates and Juri Ota-Kuroki and Martin L Katz and Rebecca E H Whiting},
journal = {Biology},
year = {2026},
month = oct,
doi = {10.3390/biology15191761},
url = {https://europepmc.org/article/MED/42883434},
note = {CC BY},
}
RIS
TY - JOUR
TI - Biofluid Proteomic Biomarker Discovery in a Large Animal Model of CLN2 Neuronal Ceroid Lipofuscinosis.
AU - Brandie R Morgan-Jack
AU - Grace R Kick
AU - Zhen Lyu
AU - Trupti Joshi
AU - Brian Mooney
AU - Joan R Coates
AU - Juri Ota-Kuroki
AU - Martin L Katz
AU - Rebecca E H Whiting
PY - 2026
DA - 2026/10/02
JO - Biology
DO - 10.3390/biology15191761
UR - https://europepmc.org/article/MED/42883434
AB - CLN2 disease is a fatal lysosomal storage disorder caused by deficiency of the lysosomal enzyme tripeptidyl peptidase 1 (TPP1), resulting in progressive neurodegeneration and non-neuronal pathology. While enzyme replacement therapy has improved disease management, there remains a critical need for objective molecular biomarkers capable of monitoring disease progression and therapeutic response. The purpose of this study was to utilize a canine model of CLN2 disease to investigate proteomic changes in cerebrospinal fluid (CSF) and in minimally invasive biofluids tears and plasma to identify candidate disease biomarkers. Untargeted proteomic analysis was conducted using these biofluids from unaffected controls and CLN2-affected dogs at presymptomatic, symptomatic, and advanced disease stages. CSF demonstrated the greatest degree of proteomic alterations over the disease progression. Proteins associated with cytoskeletal organization, synaptic signaling, lysosomal biology, mitochondrial metabolism, lipid homeostasis, and inflammatory responses were significantly altered. Tear fluid demonstrated overlapping biological themes with CSF, particularly involving mitochondrial metabolism, lysosomal function, and lipid-associated pathways. In contrast, plasma proteomic alterations were comparatively modest but supported systemic changes associated with extracellular signaling, inflammation, and lipid metabolism. Collectively, these findings demonstrate progressive and coordinated proteomic alterations across multiple biofluids in CLN2 disease that can serve as candidate biomarkers of disease progression.
SN - 2079-7737
ER -